Bone Marrow Transplant. 2023 Nov;58(Suppl 1):696-699. doi: 10.1038/s41409-023-02065-6.
NO ABSTRACT
PMID:37945730 | DOI:10.1038/s41409-023-02065-6
Sci Rep. 2023 Nov 9;13(1):19498. doi: 10.1038/s41598-023-46825-2.
ABSTRACT
The study aimed to investigate the usefulness of the Running-based Anaerobic Sprint Test (RAST) in anaerobic performance estimation in trained and untrained girls U12, and the effect of an 8-week training period in female U12 soccer players on anaerobic performance. A comparative study of two structurally different anaerobic tests was performed to reach the goal. The study was designed as a non-randomized, controlled before-and-after trial. Fourteen female soccer players (FSP) and twelve untrained girls (UNT) participated in the study. During that time, all participants were subjected to school’s physical education classes and the FSP additionally participated in regular soccer training. The anaerobic performance was evaluated twice, within 8-weeks period, using the traditional Wingate test (WAnT) and the RAST. A significant increase in the anaerobic performance of the FSP was noted (p < 0.05). In both tests peak, average, and relative power were significantly improved (p < 0.005). Nevertheless, strong, statistically significant (p < 0.05) correlation coefficients (0.50 < r < 0.70) were found for pre-training measurements between the WAnT and the RAST power parameters in absolute values. In UNT group significant improvement was found in peak, average and min power (p < 0.05) in the RAST. The improvement in anaerobic performance after training along with the strong correlation noted between the WAnT and the RAST power parameters prove the usefulness of the RAST in assessing anaerobic capacity in female youth athletes. Its simplicity encourages its use in monitoring anaerobic capacity in both trained and untrained girls.
PMID:37945713 | DOI:10.1038/s41598-023-46825-2
Sci Rep. 2023 Nov 9;13(1):19556. doi: 10.1038/s41598-023-46996-y.
ABSTRACT
The purpose of this study was to investigate the correlation between GFR and unit renal volume in infants with congenital hydronephrosis measured by 99mTc-DMSA static renal imaging and ultrasonography. According to the classification of hydronephrosis, 38 infants aged 0-12 months with congenital hydronephrosis were divided into six groups: healthy kidney groups, mild hydronephrosis groups, and severe hydronephrosis groups. Within one week, all patients underwent ultrasound, diuretic dynamic renal imaging, static renal imaging and lateral imagings of both kidneys after static renal imaging respectively. Pediatric renal volume was calculated using the improved formula length × width × thickness × 0.674, and then the renal function in per unit volume (GFR/unit volume, ml/cm3) was obtained. All statistical analysis was done with SPSS Statistics version 24.0. The renal function in per unit volume was a minimum of 1.62 ml/cm3 in left healthy kidney in static renal imaging, but the renal function in per unit volume was a maximum value of 2.20 ml/cm3 in right healthy kidney in ultrasonography. There was a strong positive correlation observed between GFR and renal volume in left healthy kidney group and left and right kidneys with mild hydronephrosis groups (r = 0.865, r = 0.872, r = 0.822). A moderate positive correlation was found between GFR and renal volume in right healthy kidney group and left and right kidneys wih severe hydronephrosis groups (r = 0.783, r = 0.542, r = 0.798). GFR in per unit volume ranged from 1.62 to 2.20 ml/cm3 in healthy kidney, and was significantly higher in right kidney as compared to in left kidney, and also decreased with the progression of hydronephrosis.
PMID:37945690 | DOI:10.1038/s41598-023-46996-y
Eval Rev. 2023 Nov 9:193841X231214824. doi: 10.1177/0193841X231214824. Online ahead of print.
ABSTRACT
With an educational issue that has caught the attention of many countries in the world (study load), a population of 8th graders from a typical Chinese metropolitan city (40,536 from 118 schools), and an advanced statistical strategy (multilevel piecewise regression), we examined whether there was a turning point in terms of the effects of study load on science achievement. We did identify a turning point for each and every measure of study load. For weekday learning on science achievement, we identified a turning point of 22.50 hr for the effects of in-school learning, 7.50 hr for the effects of homework, and 12 hr for the effects of after-school learning. For weekend learning on science achievement, we identified a turning point of 1.50 hr for the effects of in-school learning, 5 hr for the effects of homework, and 1 hr for the effects of after-school learning. In each case, the difference in effects before and after the turning point was statistically significant, indicating that the effects of study load on science achievement were nonlinear. All of these turning points offered important implications for science education.
PMID:37944185 | DOI:10.1177/0193841X231214824
Physiol Meas. 2023 Nov 9. doi: 10.1088/1361-6579/ad0b3d. Online ahead of print.
ABSTRACT
OBJECTIVE: To extend the highly successful U-Net Convolutional Neural Network architecture, which is limited to rectangular pixel/voxel domains, to a graph-based equivalent that works flexibly on irregular meshes; and demonstrate the effectiveness on Electrical Impedance Tomography (EIT).
APPROACH: By interpreting the irregular mesh as a graph, we develop a graph U-Net with new cluster pooling and unpooling layers that mimic the classic neighborhood based max-pooling important for imaging applications. Main~Results: The proposed graph U-Net is shown to be flexible and effective for improving early iterate Total Variation (TV) reconstructions from EIT measurements, using as little as the first iteration. The performance is evaluated for simulated data, and on experimental data from three measurement devices with different measurement geometries and instrumentations. We successfully show that such networks can be trained with a simple two-dimensional simulated training set, and generalize to very different domains, including measurements from a three-dimensional device and subsequent 3D reconstructions.
SIGNIFICANCE: As many inverse problems are solved on irregular (e.g. finite element) meshes, the proposed graph U-Net and pooling layers provide the added flexibility to process directly on the computational mesh. Post-processing an early iterate reconstruction greatly reduces the computational cost which can become prohibitive in higher dimensions with dense meshes. As the graph structure is independent of `dimension’, the flexibility to extend networks trained on 2D domains to 3D domains offers a possibility to further reduce computational cost in training.
PMID:37944184 | DOI:10.1088/1361-6579/ad0b3d
Obstet Gynecol. 2023 Nov 9. doi: 10.1097/AOG.0000000000005442. Online ahead of print.
ABSTRACT
OBJECTIVE: To estimate the effect of diabetes group prenatal care on rates of preterm birth and large for gestational age (LGA) among patients with diabetes in pregnancy compared with individual diabetes prenatal care.
DATA SOURCES: We searched Ovid Medline (1946-), Embase.com (1947-), Scopus (1823-), Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov.
METHODS OF STUDY SELECTION: We searched electronic databases for randomized controlled trials (RCTs) and observational studies comparing diabetes group prenatal care with individual care among patients with type 2 diabetes mellitus or gestational diabetes mellitus (GDM). The primary outcomes were preterm birth before 37 weeks of gestation and LGA (birth weight at or above the 90th percentile). Secondary outcomes were small for gestational age, cesarean delivery, neonatal hypoglycemia, neonatal intensive care unit admission, breastfeeding at hospital discharge, long-acting reversible contraception (LARC) uptake, and 6-week postpartum visit attendance. Secondary outcomes, limited to the subgroup of patients with GDM, included rates of GDM requiring diabetes medication (A2GDM) and completion of postpartum oral glucose tolerance testing (OGTT). Heterogeneity was assessed with the Cochran Q test and I2 statistic. Random-effects models were used to calculate pooled relative risks (RRs) and weighted mean differences.
TABULATION, INTEGRATION, AND RESULTS: Eight studies met study criteria and were included in the final analysis: three RCTs and five observational studies. A total of 1,701 patients were included in the pooled studies: 770 (45.3%) in diabetes group prenatal care and 931 (54.7%) in individual care. Patients in diabetes group prenatal care had similar rates of preterm birth compared with patients in individual care (seven studies: pooled rates 9.5% diabetes group prenatal care vs 11.5% individual care, pooled RR 0.77, 95% CI, 0.59-1.01), which held for RCTs and observational studies. There was no difference between diabetes group prenatal care and individual care in rates of LGA overall (four studies: pooled rate 16.7% diabetes group prenatal care vs 20.2% individual care, pooled RR 0.93, 95% CI, 0.59-1.45) or by study type. Rates of other secondary outcomes were similar between diabetes group prenatal care and individual care, except patients in diabetes group prenatal care were more likely to receive postpartum LARC (three studies: pooled rates 46.1% diabetes group prenatal care vs 34.1% individual care, pooled RR 1.44, 95% CI, 1.09-1.91). When analysis was limited to patients with GDM, there were no differences in rates of A2GDM or postpartum visit attendance, but patients in diabetes group prenatal care were significantly more likely to complete postpartum OGTT (five studies: pooled rate 74.0% diabetes group prenatal care vs 49.4% individual care, pooled RR 1.58, 95% CI, 1.19-2.09).
CONCLUSION: Patients with type 2 diabetes and GDM who participate in diabetes group prenatal care have similar rates of preterm birth, LGA, and other pregnancy outcomes compared with those who participate in individual care; however, they are significantly more likely to receive postpartum LARC, and those with GDM are more likely to return for postpartum OGTT.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42021279233.
PMID:37944148 | DOI:10.1097/AOG.0000000000005442
J Womens Health (Larchmt). 2023 Nov 10. doi: 10.1089/jwh.2023.0061. Online ahead of print.
ABSTRACT
Background: Postpartum depression (PPD) is a prevalent public health concern. Combustible cigarette use is associated with increased risk of PPD. While electronic cigarette (e-cigarette) use during pregnancy is linked to increased risk of depressive symptoms during pregnancy, the relationship between e-cigarette use and PPD is not well understood. We sought to examine the association of e-cigarette use with PPD. Materials and Methods: Using Pregnancy Risk Assessment Monitoring System 2016-2019 data, unadjusted and adjusted logistic regression analyses for PPD were conducted via three analyses where e-cigarette use (any vs. none) was retrospectively self-reported (1) in past 2-year, (2) prepregnancy (i.e., 3 months before pregnancy), and (3) during pregnancy (i.e., last 3 months of pregnancy). We conducted an additional past 2-year e-cigarette use analysis excluding those who used combustible cigarette and/or hookah. Covariates included age, race, ethnicity, combustible cigarette, and/or hookah use, prenatal care during the last trimester, health insurance coverage during pregnancy, physical abuse during pregnancy, income, and survey type. Results: Only unadjusted odds ratios from past 2-year e-cigarette use (1.63, 95% confidence interval [CI]: 1.42-1.87) and past 2-year e-cigarette use excluding individuals with cigarette and/or hookah use (1.78, 95% CI: 1.30-2.38) were statistically associated with PPD. No adjusted analyses were statistically significant. Conclusion: Any e-cigarette use, as compared to no use, does not appear to be an independent risk factor of PPD, though it may be a useful clinical marker of increased risk of PPD. Future studies are warranted to advance our knowledge of impact of e-cigarette use on PPD.
PMID:37944112 | DOI:10.1089/jwh.2023.0061
J Womens Health (Larchmt). 2023 Nov 1. doi: 10.1089/jwh.2023.0002. Online ahead of print.
ABSTRACT
Background: Social determinants of health are important contributors to maternal and child health outcomes. Limited existing research examines the relationship between housing instability during pregnancy and perinatal care utilization. Our objective was to evaluate whether antenatal housing instability is associated with differences in perinatal care utilization and outcomes. Materials and Methods: Participants who were surveyed during their postpartum hospitalization were considered to have experienced housing instability if they answered affirmatively to at least one of six screening items. The primary outcome was adequacy of prenatal care measured by the Adequacy of Prenatal Care Utilization index. Maternal, neonatal, and postpartum outcomes, including utilization and breastfeeding, were also collected as secondary outcomes. Multivariable logistic regression models were adjusted for sociodemographic and clinical covariates. Results: In this cohort (N = 490), 11.2% (N = 55) experienced housing instability during pregnancy. Participants with unstable housing were more likely to have inadequate prenatal care (17.3% vs. 3.9%; odds ratio [OR] 5.11, 95% confidence interval [CI] 2.15-12.14, p < 0.001), but findings were not significant after adjustment (aOR 1.72, 95% CI 0.55-5.41, p = 0.35). Similarly, postpartum visit attendance was lower for individuals with unstable housing (79.6% vs. 91.2%), but there was no difference in the odds of the postpartum visit attendance after adjustment (OR 0.69, 95% CI 0.29-1.66, p = 0.14). Conclusions: There were no statistically significant association with the maternal, neonatal, and other postpartum secondary outcomes. Housing instability appears to be a risk marker that is related to other social determinants of health. Given the range of housing instability experiences, future research must account for specific types and degrees of housing instability and their potential perinatal consequences.
PMID:37944106 | DOI:10.1089/jwh.2023.0002
JCO Glob Oncol. 2023 Sep;9:e2300294. doi: 10.1200/GO.23.00294.
ABSTRACT
Rapidly expanding systemic treatment options, combined with improved screening, diagnostic, surgical, and radiotherapy techniques, have led to improved survival outcomes for many cancers over time. However, these overall survival gains have disproportionately benefited patients in high-income countries, whereas patients in low- and middle-income countries (LMICs) continue to experience challenges in accessing timely and guideline concordant care. In September 2022, the Accelerating Anticancer Agent Development and Validation workshop was held, focusing on global cancer drug development. Panelists discussed key barriers such as the lack of diagnostic services and human resources, drug accessibility and affordability, lack of research infrastructure, and regulatory and authorization challenges, with a particular focus on Africa and Latin America. Potential opportunities to improve access and affordability were reviewed, such as the importance of prioritizing investments in diagnostics, investing health infrastructure and work force planning, coordinated drug procurement efforts and streamlined regulatory processing, incentivized pricing through regulatory change, and the importance of developing and promoting clinical trials that can answer relevant clinical questions for patients in LMICs. As a cancer community, we must continue to advocate for and work toward equitable access to high-quality interventions for patients, regardless of their geographical location.
PMID:37944089 | DOI:10.1200/GO.23.00294
J Clin Oncol. 2023 Nov 9:JCO2301193. doi: 10.1200/JCO.23.01193. Online ahead of print.
ABSTRACT
PURPOSE: Human epidermal growth factor receptor 2 (HER2) overexpression is seen in 4%-16% of biliary tract cancers (BTCs). We aimed to evaluate the clinical activity of gemcitabine-cisplatin (GC) plus anti-HER2 antibody trastuzumab as initial treatment in HER2-positive BTCs.
METHODS: This study was an investigator-initiated, open-label, single-arm, multi-institutional, phase II trial in adult patients with HER2-positive (defined as immunohistochemistry [IHC] 3+ or IHC 2+ and fluorescent in situ hybridization-positive), treatment-naïve BTCs. The primary end point of the study was 6-month progression-free survival (PFS). Next-generation sequencing was performed on tissue samples to evaluate mutational status.
RESULTS: From March 2020 to August 2022, of the 876 screened patients, 118 (13.4%) were found to have HER2-positive status, of whom 90 were enrolled in the study. Most patients had GBC (n = 96; 96%) with two or more sites of metastatic disease (n = 70; 78%). With a median follow-up of 17.3 (95% CI, 15.22 to 19.32) months, 72 patients had disease progression with a median PFS of 7 (95% CI, 6.2 to 7.8) months. The diagnosis to event 6-month PFS rate was 75.6% (95% CI, 66.6 to 84.6). A complete or partial response was seen in 50 (55.5%) patients and 22 (24.4%) patients had stable disease as the best response to treatment, for an overall disease control rate of 80%. The presence of isolated TP53 mutations was associated with inferior PFS compared with other mutations (TERT promoter, HER2, PIK3CA, etc) or no detected mutations (6.51 v 12.02 v 10.58 months; P < .001).
CONCLUSION: The combination of GC and trastuzumab achieved its primary end point of improving PFS compared with historical data in the treatment-naïve HER2-positive BTC. Evaluating additional mutations such as TP53 and PIK3CA along with HER2 testing may help to preferentially select patients for anti-HER2 therapy in the future (Clinical Trial Registry India number: CTRI/2019/11/021955).
PMID:37944079 | DOI:10.1200/JCO.23.01193